Mallinckrodt Pharmaceuticals (NYSE:MNK) issued a response today to Sen. Claire McCaskill (D-Mo.) and her probe into the company’s pricing strategies for its injectable pain-killer, Ofirmev. McCaskill wrote to the company at the end of May, suggesting that that the company’s price increases could have cost hospitals millions and may have pushed healthcare practitioners to use cheaper painkillers, including highly […]
Pain Management
Adapt Pharma touts usability data for Narcan nasal spray
Adapt Pharma touted data today from 2 human factors studies that evaluated the usability of its Narcan nasal spray by adolescents and people with low literacy. The Dublin-based company’s product is a ready-to-use, needle-free device that delivers a single dose of naloxone in a nasal spray to someone experiencing an opioid overdose and does not require […]
Braeburn, Knight seek Health Canada nod for opioid dependence implant
Braeburn Pharmaceuticals and Knight Therapeutics (TSE:GUD) said today that Health Canada has agreed to review Knight’s new drug submission for Probuphine, a buprenorphine subdermal implant designed to treat opioid drug dependence. In February last year, Braeburn and Knight inked an exclusive distribution and sublicense deal, giving Knight the exclusive right to distribute Probuphine in Canada. Get […]
Milestone Scientific wins 510(k) clearance for epidural anesthesia system
Milestone Scientific (NYSE:MLSS) said today that its CompuFlo epidural computer-controlled anesthesia system won 510(k) clearance from the FDA. The Livingston, N.J.-based company’s CompuFlo Epidural instrument uses dynamic pressure sensing to help anesthesiologists correctly identify the epidural space and significantly reduce complications in real-time, according to Milestone. Get the full story at our sister site, Drug […]
FDA asks Endo to pull Opana from the market over concerns of abuse
The FDA asked Endo Pharmaceuticals (NSDQ:ENDP) to pull its opioid pain med, Opana ER, from the market, saying that the benefits of the abuse-deterrent drug no longer outweigh the risks. The move marks the 1st time the federal regulatory watchdog has urged a company to remove an opioid painkiller due to concerns of abuse. Get the full […]
ElectroCore touts gammaCore cluster headache trial data
Neuroscience tech developer ElectroCore today released data from the ACT clinical trials exploring the use of its gammaCore non-invasive vagus nerve stimulator for treating patients with episodic cluster headaches. Results from the study were presented at the 59th Annual Scientific Meeting of the American Headache Society, the company said. The 250-patient studies evaluated the safety and efficacy of the […]
Critics allege misleading campaigns, poorly-cited data fueled opioid addiction crisis
The state of Ohio filed a lawsuit against opioid-makers this week, alleging that the companies produced misleading marketing schemes to convince doctors and patients that opioids were not addictive. This was a huge problem throughout the state, everybody knows that it can be very addictive and that’s why it is important to get Ibogaine Treatment […]
BioElectronic launches migraine study for ActiPatch pulsed shortwave therapy
Non-invasive electroceutical developer BioElectronics said today it launched a clinical study of its ActiPatch, examining the use of the device for treating migraines. The ActiPatch is a series of patches or wraps which use electromagnetic pulse therapy to treat chronic pain, according to the Frederick, Md.-based company’s website. In the randomized, double-blinded placebo controlled study, […]
Mallinckrodt faces probe over price hikes for injectable pain-killer
Sen. Claire McCaskill (D-Mo.) penned a letter to Mallinckrodt Pharmaceuticals (NYSE:MNK) last week, probing for details about the company’s pricing strategies for its injectable pain-killer, Ofirmev. Mallinckrodt acquired Ofirmev in 2014, when it bought Cadence Pharmaceuticals in a $1.4 billion deal. In May of that year, Mallinckrodt hiked the pain-killer’s list price from $14.75 per vial to […]
Revive Therapeutics, University of Wisconsin-Madison ink deal for cannabinoid drug delivery tech
Revive Therapeutics (OTC:RVVTF) said today that it inked a research agreement with the University of Wisconsin-Madison to develop a drug delivery technology for cannibinoids. The research program, led by Jess Reed, is slated to evaluate chitosan-tannin composite biomaterial as a delivery mechanism for cannabinoids. Therapeutic biomaterials made from a composite of chitosan and tannin include […]
Tactile Systems launches Flexitouch lymphedema device
Tactile Systems Technology said today it launched its Flexitouch device designed to treat lymphedema of the head and neck, touting it as the 1st and only pneumatic compression therapy approved for the condition. The Flexitouch device is designed to use pneumatic compression to stimulate the lymphatic system to deliver non-invasive, self-delivered therapy for lymphedema, which is […]